Key Points
- CFO Hunter Smith sold 3,247 shares on Feb. 4 at an average price of $105.99 for a total of $344,149.53, trimming his position by 2.46% to 128,918 shares worth about $13.66 million.
- Rhythm reported a quarterly EPS of ($0.82), missing consensus ($0.72) and showing a negative ROE (433.21%) and net margin (-110.32%), though revenue of $51.3 million slightly beat estimates.
- Wall Street sentiment is mixed but leans positive with a consensus rating of "Moderate Buy" and a $131.29 price target, while large institutions like Vanguard have significantly increased stakes (Vanguard now owns ~6.21 million shares).
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter Smith sold 3,247 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $105.99, for a total value of $344,149.53. Following the transaction, the chief financial officer owned 128,918 shares in the company, valued at $13,664,018.82. The trade was a 2.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rhythm Pharmaceuticals Stock Performance
RYTM opened at $103.61 on Friday. The stock has a fifty day moving average of $106.59 and a 200-day moving average of $102.36. The company has a market capitalization of $6.91 billion, a P/E ratio of -33.42 and a beta of 2.00. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The business had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.71 million. On average, equities research analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on RYTM shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. Zacks Research downgraded Rhythm Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, January 19th. Needham & Company LLC increased their target price on Rhythm Pharmaceuticals from $145.00 to $148.00 and gave the stock a "buy" rating in a report on Friday, January 9th. UBS Group reaffirmed a "buy" rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, December 17th. Finally, HC Wainwright increased their price objective on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the stock a "buy" rating in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $131.29.
View Our Latest Stock Analysis on RYTM
Institutional Investors Weigh In On Rhythm Pharmaceuticals
A number of hedge funds have recently made changes to their positions in RYTM. Vanguard Group Inc. increased its position in Rhythm Pharmaceuticals by 24.3% during the 4th quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company's stock worth $664,816,000 after purchasing an additional 1,214,489 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Rhythm Pharmaceuticals by 2.2% during the third quarter. RA Capital Management L.P. now owns 5,681,359 shares of the company's stock worth $573,760,000 after buying an additional 120,000 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 2.5% during the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company's stock worth $174,499,000 after buying an additional 41,391 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Rhythm Pharmaceuticals by 21.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company's stock valued at $102,966,000 after acquiring an additional 288,376 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,311,253 shares of the company's stock valued at $82,868,000 after acquiring an additional 24,085 shares in the last quarter.
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
